{"id":1038,"date":"2024-02-25T14:52:45","date_gmt":"2024-02-25T13:52:45","guid":{"rendered":"https:\/\/www.utopiasis.it\/?page_id=1038"},"modified":"2024-03-08T08:10:39","modified_gmt":"2024-03-08T07:10:39","slug":"novavido-srl","status":"publish","type":"page","link":"https:\/\/www.utopiasis.it\/en\/novavido-srl\/","title":{"rendered":"\u00a0Novavido Srl"},"content":{"rendered":"\n[et_pb_section fb_built=”1″ admin_label=”sezione blocco 1″ _builder_version=”4.24.2″ _module_preset=”default” background_color=”gcid-ac150a38-2027-4fd4-8963-25e8b6f6f839″ custom_margin=”85px||||false|false” custom_padding=”0px||0px||false|false” global_colors_info=”{%22gcid-ac150a38-2027-4fd4-8963-25e8b6f6f839%22:%91%22background_color%22%93}”][et_pb_row column_structure=”1_2,1_2″ use_custom_gutter=”on” gutter_width=”1″ make_equal=”on” _builder_version=”4.24.2″ _module_preset=”default” width=”100%” max_width=”100%” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.24.2″ _module_preset=”default” background_image=”https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/beautiful-macro-closeup-shot-female-human-s-deep-eyes-scaled.jpg” background_enable_video_mp4=”off” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/Novavido.png” title_text=”Novavido” _builder_version=”4.24.2″ _module_preset=”default” background_color=”#FFFFFF” positioning=”absolute” position_origin_a=”bottom_left” width=”35%” custom_margin=”||||false|false” custom_padding=”20px|20px|20px|20px|false|false” locked=”off” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.24.2″ _module_preset=”default” custom_padding=”100px|60px|100px|60px|true|true” global_colors_info=”{}”][et_pb_text _builder_version=”4.24.2″ _module_preset=”default” header_2_text_color=”gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14″ header_2_font_size=”30px” custom_margin=”||0px||false|false” locked=”off” global_colors_info=”{%22gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14%22:%91%22header_2_text_color%22%93}”]

Novavido<\/h2>[\/et_pb_text][et_pb_divider color=”gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14″ _builder_version=”4.24.2″ _module_preset=”default” custom_margin=”||0px||false|false” custom_padding=”||||false|false” locked=”off” global_colors_info=”{%22gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14%22:%91%22color%22%93}”][\/et_pb_divider][et_pb_text _builder_version=”4.24.2″ _module_preset=”default” header_4_text_color=”gcid-b7a20a05-ac47-46ee-846a-44540a53bb38″ header_4_line_height=”1.4em” hover_enabled=”0″ global_colors_info=”{%22gcid-b7a20a05-ac47-46ee-846a-44540a53bb38%22:%91%22header_4_text_color%22%93}” sticky_enabled=”0″]

NOVAVIDO: THE START-UP THAT WILL STUDY THE FIRST LIQUID ARTIFICIAL RETINA IN HUMANS<\/h4>[\/et_pb_text][et_pb_text _builder_version=”4.24.2″ _module_preset=”default” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” text_orientation=”justified” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]A start-up of the Italian Institute of Technology (IIT) in which Utopia has invested together with AlfaSigma, Fondazione Chiossone, and Club 2021.\n\nThe financial and technological intervention provided by AlfaSigma is a project concerning the development of an injectable and biocompatible device called ‘liquid retina,’ which would enable partial vision recovery for individuals affected by partial blindness caused by degenerative retinal diseases.[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_6,1_6,1_6″ use_custom_gutter=”on” gutter_width=”1″ make_equal=”on” _builder_version=”4.24.2″ _module_preset=”default” width=”100%” max_width=”100%” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.24.2″ _module_preset=”default” custom_padding=”100px|60px|100px|60px|true|true” global_colors_info=”{}”][et_pb_text _builder_version=”4.24.2″ _module_preset=”default” text_text_color=”#000000″ text_font_size=”17px” text_line_height=”1.8em” text_orientation=”justified” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]The research has been developed over a period of 10 years by the Center for Nano Science and Technology (CNST-IIT Milan) led by Guglielmo Lanzani and the Center for Synaptic Neuroscience and Technology (NSYN-IIT Genoa) led by Fabio Benfenati, in collaboration with Grazia Pertile and Maurizio Mete from the IRCCS Ospedale Sacro Cuore Don Calabria in Negrar (Verona). Novavido S.r.l. is a start-up accelerated within the G-Factor incubator of Fondazione Golinelli.\n\nUtopia invested in 2021.[\/et_pb_text][et_pb_blurb title=”www.novavido.it” url=”https:\/\/www.novavido.it\/it\/” url_new_window=”on” use_icon=”on” font_icon=”I||divi||400″ icon_color=”gcid-b7a20a05-ac47-46ee-846a-44540a53bb38″ icon_placement=”left” _builder_version=”4.24.2″ _module_preset=”default” header_font=”||||||||” header_font_size=”17px” custom_margin=”||||false|false” custom_padding=”30px||||false|false” global_colors_info=”{%22gcid-b7a20a05-ac47-46ee-846a-44540a53bb38%22:%91%22icon_color%22%93}”][\/et_pb_blurb][\/et_pb_column][et_pb_column type=”1_6″ _builder_version=”4.24.2″ _module_preset=”default” background_color=”gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14″ custom_padding=”20px|20px|20px|20px|true|true” global_colors_info=”{%22gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14%22:%91%22background_color%22%93}”][et_pb_image src=”https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/parlano-di-noi-4.png” title_text=”parlano di noi (4)” url=”https:\/\/www.fondazionegolinelli.it\/media\/Gpanoramait230820215951629799412.pdf” url_new_window=”on” _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_image src=”https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/parlano-di-noi-3.png” title_text=”parlano di noi (3)” url=”https:\/\/dealflower.it\/utopia-sis-e-altri-nel-round-da-6-milioni-della-startup-novavido\/” url_new_window=”on” _builder_version=”4.24.2″ _module_preset=”default” custom_margin=”30px||||false|false” global_colors_info=”{}”][\/et_pb_image][et_pb_image src=”https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/15.png” title_text=”15″ url=”https:\/\/www.aboutpharma.com\/aziende\/novavido-startup-retina-artificiale-liquida\/” url_new_window=”on” _builder_version=”4.24.2″ _module_preset=”default” custom_margin=”30px||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”1_6″ _builder_version=”4.24.2″ _module_preset=”default” background_color=”gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14″ custom_padding=”20px|20px|20px|20px|true|true” global_colors_info=”{%22gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14%22:%91%22background_color%22%93}”][et_pb_image src=”https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/parlano-di-noi-1.png” title_text=”parlano di noi (1)” url=”https:\/\/bebeez.it\/venture-capital\/le-protesi-retiniche-novavido-accelerate-da-g-factor-fondazione-golinelli-chiudono-round-da-6-mln-euro\/” url_new_window=”on” _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_image src=”https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/1.png” title_text=”1″ url=”https:\/\/www.corriere.it\/economia\/aziende\/21_giugno_23\/retina-artificiale-liquida-sull-uomo-l-iit-lancia-nuova-startup-62ccc5cc-d3fa-11eb-8dcd-923bd7ac4a6d.shtml” url_new_window=”on” _builder_version=”4.24.2″ _module_preset=”default” custom_margin=”30px||||false|false” global_colors_info=”{}”][\/et_pb_image][et_pb_image src=”https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/parlano-di-noi-6.png” title_text=”parlano di noi” url=”https:\/\/www.affaritaliani.it\/medicina\/novadido-nasce-la-start-up-che-studiera-la-prima-retina-artificiale-liquida-746590.html#google_vignette” url_new_window=”on” _builder_version=”4.24.2″ _module_preset=”default” custom_margin=”30px||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”1_6″ _builder_version=”4.24.2″ _module_preset=”default” background_color=”gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14″ custom_padding=”20px|20px|20px|20px|true|true” global_colors_info=”{%22gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14%22:%91%22background_color%22%93}”][et_pb_image src=”https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/8.png” title_text=”8″ url=”https:\/\/startupitalia.eu\/startup\/investimenti\/novavido-la-startup-della-prima-retina-liquida-artificiale-chiude-un-round-da-6-milioni-di-euro\/” url_new_window=”on” _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_image src=”https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/parlano-di-noi-5.png” title_text=”parlano di noi (5)” url=”https:\/\/www.ilrestodelcarlino.it\/speciali\/alfasigma\/novavido-e-r-and-d-alfasigma-progressi-verso-la-retina-artificiale-liquida-cde3e392″ url_new_window=”on” _builder_version=”4.24.2″ _module_preset=”default” custom_margin=”30px||||false|false” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.24.2″ _module_preset=”default” background_color=”gcid-b7a20a05-ac47-46ee-846a-44540a53bb38″ background_enable_mask_style=”on” background_mask_style=”triangles” background_mask_color=”gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14″ background_mask_transform=”invert” global_colors_info=”{%22gcid-b7a20a05-ac47-46ee-846a-44540a53bb38%22:%91%22background_color%22%93,%22gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14%22:%91%22background_mask_color%22%93}”][et_pb_row column_structure=”1_3,1_3,1_3″ use_custom_gutter=”on” gutter_width=”2″ make_equal=”on” _builder_version=”4.24.2″ _module_preset=”default” width=”90%” max_width=”100%” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/youtu.be\/S3K2J_sQyBo?si=aZ2_OVVkerj3Agr-” _builder_version=”4.24.2″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_video][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/www.youtube.com\/live\/6SD1K9mZ7DY?si=mO6LlZ_S1eTdikLo” _builder_version=”4.24.2″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_video][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/www.youtube.com\/watch?v=N0FJLPVu9MY” _builder_version=”4.24.2″ _module_preset=”default” custom_margin=”||||false|false” global_colors_info=”{}”][\/et_pb_video][\/et_pb_column][\/et_pb_row][\/et_pb_section]\n","protected":false},"excerpt":{"rendered":"

NovavidoNOVAVIDO: THE START-UP THAT WILL STUDY THE FIRST LIQUID ARTIFICIAL RETINA IN HUMANSA start-up of the Italian Institute of Technology (IIT) in which Utopia has invested together with AlfaSigma, Fondazione Chiossone, and Club 2021. The financial and technological intervention provided by AlfaSigma is a project concerning the development of an injectable and biocompatible device called […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"[et_pb_section fb_built=\"1\" admin_label=\"sezione blocco 1\" _builder_version=\"4.24.2\" _module_preset=\"default\" background_color=\"gcid-ac150a38-2027-4fd4-8963-25e8b6f6f839\" custom_margin=\"85px||||false|false\" custom_padding=\"0px||0px||false|false\" global_colors_info=\"{%22gcid-ac150a38-2027-4fd4-8963-25e8b6f6f839%22:%91%22background_color%22%93}\"][et_pb_row column_structure=\"1_2,1_2\" use_custom_gutter=\"on\" gutter_width=\"1\" make_equal=\"on\" _builder_version=\"4.24.2\" _module_preset=\"default\" width=\"100%\" max_width=\"100%\" custom_padding=\"0px||0px||false|false\" global_colors_info=\"{}\"][et_pb_column type=\"1_2\" _builder_version=\"4.24.2\" _module_preset=\"default\" background_image=\"https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/beautiful-macro-closeup-shot-female-human-s-deep-eyes-scaled.jpg\" background_enable_video_mp4=\"off\" global_colors_info=\"{}\"][et_pb_image src=\"https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/Novavido.png\" title_text=\"Novavido\" _builder_version=\"4.24.2\" _module_preset=\"default\" background_color=\"#FFFFFF\" positioning=\"absolute\" position_origin_a=\"bottom_left\" width=\"35%\" custom_margin=\"||||false|false\" custom_padding=\"20px|20px|20px|20px|false|false\" locked=\"off\" global_colors_info=\"{}\"][\/et_pb_image][\/et_pb_column][et_pb_column type=\"1_2\" _builder_version=\"4.24.2\" _module_preset=\"default\" custom_padding=\"100px|60px|100px|60px|true|true\" global_colors_info=\"{}\"][et_pb_text _builder_version=\"4.24.2\" _module_preset=\"default\" header_2_text_color=\"gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14\" header_2_font_size=\"30px\" custom_margin=\"||0px||false|false\" locked=\"off\" global_colors_info=\"{%22gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14%22:%91%22header_2_text_color%22%93}\"]\n

Novavido<\/h2>\n[\/et_pb_text][et_pb_divider color=\"gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14\" _builder_version=\"4.24.2\" _module_preset=\"default\" custom_margin=\"||0px||false|false\" custom_padding=\"||||false|false\" locked=\"off\" global_colors_info=\"{%22gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14%22:%91%22color%22%93}\"][\/et_pb_divider][et_pb_text _builder_version=\"4.24.2\" _module_preset=\"default\" header_4_text_color=\"gcid-b7a20a05-ac47-46ee-846a-44540a53bb38\" header_4_line_height=\"1.4em\" global_colors_info=\"{%22gcid-b7a20a05-ac47-46ee-846a-44540a53bb38%22:%91%22header_4_text_color%22%93}\"]\n

NOVAVIDO: LA START-UP CHE STUDIER\u00c0 SULL\u2019UOMO LA PRIMA RETINA ARTIFICIALE LIQUIDA<\/h4>\n[\/et_pb_text][et_pb_text _builder_version=\"4.24.2\" _module_preset=\"default\" text_text_color=\"#000000\" text_font_size=\"17px\" text_line_height=\"1.8em\" text_orientation=\"justified\" global_colors_info=\"{}\"]\n\nStart-up dell\u2019Istituto Italiano di Tecnologia (IIT) in cui Utopia ha investo insieme ad AlfaSigma, Fondazione Chiossone e Club 2021.\n\nL\u2019intervento finanziario e tecnologico fornito da AlfaSigma \u00e8 un progetto che riguarda lo sviluppo di un dispositivo iniettabile e biocompatibile definito \u2018retina liquida\u2019 che consentirebbe un recupero parziale della visione alle persone affette da cecit\u00e0 parziale causata da malattie degenerative della retina.\n\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=\"1_2,1_6,1_6,1_6\" use_custom_gutter=\"on\" gutter_width=\"1\" make_equal=\"on\" _builder_version=\"4.24.2\" _module_preset=\"default\" width=\"100%\" max_width=\"100%\" custom_padding=\"0px||0px||false|false\" global_colors_info=\"{}\"][et_pb_column type=\"1_2\" _builder_version=\"4.24.2\" _module_preset=\"default\" custom_padding=\"100px|60px|100px|60px|true|true\" global_colors_info=\"{}\"][et_pb_text _builder_version=\"4.24.2\" _module_preset=\"default\" text_text_color=\"#000000\" text_font_size=\"17px\" text_line_height=\"1.8em\" text_orientation=\"justified\" hover_enabled=\"0\" global_colors_info=\"{}\" sticky_enabled=\"0\"]\n\nLa ricerca \u00e8 stata sviluppata nel corso di 10 anni dal Center for Nano Science and Technology (CNST-IIT Milano) guidato da Guglielmo Lanzani e dal Center for Synaptic Neuroscience and Technology (NSYN-IIT Genova) guidato da Fabio Benfenati, in collaborazione con Grazia Pertile e Maurizio Mete dell\u2019IRCCS Ospedale Sacro Cuore Don Calabria di Negrar (Verona). Novavido S.r.l. \u00e8 una Start-up accelerata nell\u2019incubatore G-Factor della Fondazione Golinelli.\n\nUtopia ha investito nel 2021.\n\n[\/et_pb_text][et_pb_blurb title=\"www.novavido.it\" url=\"https:\/\/www.novavido.it\/it\/\" url_new_window=\"on\" use_icon=\"on\" font_icon=\"I||divi||400\" icon_color=\"gcid-b7a20a05-ac47-46ee-846a-44540a53bb38\" icon_placement=\"left\" _builder_version=\"4.24.2\" _module_preset=\"default\" header_font=\"||||||||\" header_font_size=\"17px\" custom_margin=\"||||false|false\" custom_padding=\"30px||||false|false\" global_colors_info=\"{%22gcid-b7a20a05-ac47-46ee-846a-44540a53bb38%22:%91%22icon_color%22%93}\"][\/et_pb_blurb][\/et_pb_column][et_pb_column type=\"1_6\" _builder_version=\"4.24.2\" _module_preset=\"default\" background_color=\"gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14\" custom_padding=\"20px|20px|20px|20px|true|true\" global_colors_info=\"{%22gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14%22:%91%22background_color%22%93}\"][et_pb_image src=\"https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/parlano-di-noi-4.png\" title_text=\"parlano di noi (4)\" url=\"https:\/\/www.fondazionegolinelli.it\/media\/Gpanoramait230820215951629799412.pdf\" url_new_window=\"on\" _builder_version=\"4.24.2\" _module_preset=\"default\" global_colors_info=\"{}\"][\/et_pb_image][et_pb_image src=\"https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/parlano-di-noi-3.png\" title_text=\"parlano di noi (3)\" url=\"https:\/\/dealflower.it\/utopia-sis-e-altri-nel-round-da-6-milioni-della-startup-novavido\/\" url_new_window=\"on\" _builder_version=\"4.24.2\" _module_preset=\"default\" custom_margin=\"30px||||false|false\" global_colors_info=\"{}\"][\/et_pb_image][et_pb_image src=\"https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/15.png\" title_text=\"15\" url=\"https:\/\/www.aboutpharma.com\/aziende\/novavido-startup-retina-artificiale-liquida\/\" url_new_window=\"on\" _builder_version=\"4.24.2\" _module_preset=\"default\" custom_margin=\"30px||||false|false\" global_colors_info=\"{}\"][\/et_pb_image][\/et_pb_column][et_pb_column type=\"1_6\" _builder_version=\"4.24.2\" _module_preset=\"default\" background_color=\"gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14\" custom_padding=\"20px|20px|20px|20px|true|true\" global_colors_info=\"{%22gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14%22:%91%22background_color%22%93}\"][et_pb_image src=\"https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/parlano-di-noi-1.png\" title_text=\"parlano di noi (1)\" url=\"https:\/\/bebeez.it\/venture-capital\/le-protesi-retiniche-novavido-accelerate-da-g-factor-fondazione-golinelli-chiudono-round-da-6-mln-euro\/\" url_new_window=\"on\" _builder_version=\"4.24.2\" _module_preset=\"default\" global_colors_info=\"{}\"][\/et_pb_image][et_pb_image src=\"https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/1.png\" title_text=\"1\" url=\"https:\/\/www.corriere.it\/economia\/aziende\/21_giugno_23\/retina-artificiale-liquida-sull-uomo-l-iit-lancia-nuova-startup-62ccc5cc-d3fa-11eb-8dcd-923bd7ac4a6d.shtml\" url_new_window=\"on\" _builder_version=\"4.24.2\" _module_preset=\"default\" custom_margin=\"30px||||false|false\" global_colors_info=\"{}\"][\/et_pb_image][et_pb_image src=\"https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/parlano-di-noi-6.png\" title_text=\"parlano di noi\" url=\"https:\/\/www.affaritaliani.it\/medicina\/novadido-nasce-la-start-up-che-studiera-la-prima-retina-artificiale-liquida-746590.html#google_vignette\" url_new_window=\"on\" _builder_version=\"4.24.2\" _module_preset=\"default\" custom_margin=\"30px||||false|false\" global_colors_info=\"{}\"][\/et_pb_image][\/et_pb_column][et_pb_column type=\"1_6\" _builder_version=\"4.24.2\" _module_preset=\"default\" background_color=\"gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14\" custom_padding=\"20px|20px|20px|20px|true|true\" global_colors_info=\"{%22gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14%22:%91%22background_color%22%93}\"][et_pb_image src=\"https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/8.png\" title_text=\"8\" url=\"https:\/\/startupitalia.eu\/startup\/investimenti\/novavido-la-startup-della-prima-retina-liquida-artificiale-chiude-un-round-da-6-milioni-di-euro\/\" url_new_window=\"on\" _builder_version=\"4.24.2\" _module_preset=\"default\" global_colors_info=\"{}\"][\/et_pb_image][et_pb_image src=\"https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/03\/parlano-di-noi-5.png\" title_text=\"parlano di noi (5)\" url=\"https:\/\/www.ilrestodelcarlino.it\/speciali\/alfasigma\/novavido-e-r-and-d-alfasigma-progressi-verso-la-retina-artificiale-liquida-cde3e392\" url_new_window=\"on\" _builder_version=\"4.24.2\" _module_preset=\"default\" custom_margin=\"30px||||false|false\" global_colors_info=\"{}\"][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\"1\" _builder_version=\"4.24.2\" _module_preset=\"default\" background_color=\"gcid-b7a20a05-ac47-46ee-846a-44540a53bb38\" background_enable_mask_style=\"on\" background_mask_style=\"triangles\" background_mask_color=\"gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14\" background_mask_transform=\"invert\" global_colors_info=\"{%22gcid-b7a20a05-ac47-46ee-846a-44540a53bb38%22:%91%22background_color%22%93,%22gcid-e5dce679-c214-4f4d-9539-b4f3d3cd1a14%22:%91%22background_mask_color%22%93}\"][et_pb_row column_structure=\"1_3,1_3,1_3\" use_custom_gutter=\"on\" gutter_width=\"2\" make_equal=\"on\" _builder_version=\"4.24.2\" _module_preset=\"default\" width=\"90%\" max_width=\"100%\" global_colors_info=\"{}\"][et_pb_column type=\"1_3\" _builder_version=\"4.24.2\" _module_preset=\"default\" global_colors_info=\"{}\"][et_pb_video src=\"https:\/\/youtu.be\/S3K2J_sQyBo?si=aZ2_OVVkerj3Agr-\" _builder_version=\"4.24.2\" _module_preset=\"default\" custom_margin=\"||||false|false\" global_colors_info=\"{}\"][\/et_pb_video][\/et_pb_column][et_pb_column type=\"1_3\" _builder_version=\"4.24.2\" _module_preset=\"default\" global_colors_info=\"{}\"][et_pb_video src=\"https:\/\/www.youtube.com\/live\/6SD1K9mZ7DY?si=mO6LlZ_S1eTdikLo\" _builder_version=\"4.24.2\" _module_preset=\"default\" custom_margin=\"||||false|false\" global_colors_info=\"{}\"][\/et_pb_video][\/et_pb_column][et_pb_column type=\"1_3\" _builder_version=\"4.24.2\" _module_preset=\"default\" global_colors_info=\"{}\"][et_pb_video src=\"https:\/\/www.youtube.com\/watch?v=N0FJLPVu9MY\" _builder_version=\"4.24.2\" _module_preset=\"default\" custom_margin=\"||||false|false\" global_colors_info=\"{}\"][\/et_pb_video][\/et_pb_column][\/et_pb_row][\/et_pb_section]","_et_gb_content_width":"","footnotes":""},"class_list":["post-1038","page","type-page","status-publish","hentry"],"yoast_head":"\n\u00a0Novavido Srl - UTOPIA SOCIETA' DI INVESTIMENTO SEMPLICE<\/title>\n<meta name=\"description\" content=\"THE START-UP THAT WILL STUDY THE FIRST LIQUID ARTIFICIAL RETINA IN HUMANS is a project concerning the development of an injectable and biocompatible device called \u2018liquid retina,\u2019 which would enable partial vision recovery for individuals affected by partial blindness caused by degenerative retinal diseases\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.utopiasis.it\/en\/novavido-srl\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00a0Novavido Srl - UTOPIA SOCIETA' DI INVESTIMENTO SEMPLICE\" \/>\n<meta property=\"og:description\" content=\"THE START-UP THAT WILL STUDY THE FIRST LIQUID ARTIFICIAL RETINA IN HUMANS is a project concerning the development of an injectable and biocompatible device called \u2018liquid retina,\u2019 which would enable partial vision recovery for individuals affected by partial blindness caused by degenerative retinal diseases\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.utopiasis.it\/en\/novavido-srl\/\" \/>\n<meta property=\"og:site_name\" content=\"UTOPIA SOCIETA' DI INVESTIMENTO SEMPLICE\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-08T07:10:39+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.utopiasis.it\/en\/novavido-srl\/\",\"url\":\"https:\/\/www.utopiasis.it\/en\/novavido-srl\/\",\"name\":\"\u00a0Novavido Srl - UTOPIA SOCIETA' DI INVESTIMENTO SEMPLICE\",\"isPartOf\":{\"@id\":\"https:\/\/utopia.p82.it\/#website\"},\"datePublished\":\"2024-02-25T13:52:45+00:00\",\"dateModified\":\"2024-03-08T07:10:39+00:00\",\"description\":\"THE START-UP THAT WILL STUDY THE FIRST LIQUID ARTIFICIAL RETINA IN HUMANS is a project concerning the development of an injectable and biocompatible device called \u2018liquid retina,\u2019 which would enable partial vision recovery for individuals affected by partial blindness caused by degenerative retinal diseases\",\"breadcrumb\":{\"@id\":\"https:\/\/www.utopiasis.it\/en\/novavido-srl\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.utopiasis.it\/en\/novavido-srl\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.utopiasis.it\/en\/novavido-srl\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.utopiasis.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00a0Novavido Srl\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/utopia.p82.it\/#website\",\"url\":\"https:\/\/utopia.p82.it\/\",\"name\":\"utopia sis\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/utopia.p82.it\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/utopia.p82.it\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/utopia.p82.it\/#organization\",\"name\":\"utopia sis\",\"url\":\"https:\/\/utopia.p82.it\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/utopia.p82.it\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/02\/logo-utopia-v-buona.jpg\",\"contentUrl\":\"https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/02\/logo-utopia-v-buona.jpg\",\"width\":569,\"height\":191,\"caption\":\"utopia sis\"},\"image\":{\"@id\":\"https:\/\/utopia.p82.it\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00a0Novavido Srl - UTOPIA SOCIETA' DI INVESTIMENTO SEMPLICE","description":"THE START-UP THAT WILL STUDY THE FIRST LIQUID ARTIFICIAL RETINA IN HUMANS is a project concerning the development of an injectable and biocompatible device called \u2018liquid retina,\u2019 which would enable partial vision recovery for individuals affected by partial blindness caused by degenerative retinal diseases","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.utopiasis.it\/en\/novavido-srl\/","og_locale":"en_US","og_type":"article","og_title":"\u00a0Novavido Srl - UTOPIA SOCIETA' DI INVESTIMENTO SEMPLICE","og_description":"THE START-UP THAT WILL STUDY THE FIRST LIQUID ARTIFICIAL RETINA IN HUMANS is a project concerning the development of an injectable and biocompatible device called \u2018liquid retina,\u2019 which would enable partial vision recovery for individuals affected by partial blindness caused by degenerative retinal diseases","og_url":"https:\/\/www.utopiasis.it\/en\/novavido-srl\/","og_site_name":"UTOPIA SOCIETA' DI INVESTIMENTO SEMPLICE","article_modified_time":"2024-03-08T07:10:39+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.utopiasis.it\/en\/novavido-srl\/","url":"https:\/\/www.utopiasis.it\/en\/novavido-srl\/","name":"\u00a0Novavido Srl - UTOPIA SOCIETA' DI INVESTIMENTO SEMPLICE","isPartOf":{"@id":"https:\/\/utopia.p82.it\/#website"},"datePublished":"2024-02-25T13:52:45+00:00","dateModified":"2024-03-08T07:10:39+00:00","description":"THE START-UP THAT WILL STUDY THE FIRST LIQUID ARTIFICIAL RETINA IN HUMANS is a project concerning the development of an injectable and biocompatible device called \u2018liquid retina,\u2019 which would enable partial vision recovery for individuals affected by partial blindness caused by degenerative retinal diseases","breadcrumb":{"@id":"https:\/\/www.utopiasis.it\/en\/novavido-srl\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.utopiasis.it\/en\/novavido-srl\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.utopiasis.it\/en\/novavido-srl\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.utopiasis.it\/en\/"},{"@type":"ListItem","position":2,"name":"\u00a0Novavido Srl"}]},{"@type":"WebSite","@id":"https:\/\/utopia.p82.it\/#website","url":"https:\/\/utopia.p82.it\/","name":"utopia sis","description":"","publisher":{"@id":"https:\/\/utopia.p82.it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/utopia.p82.it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/utopia.p82.it\/#organization","name":"utopia sis","url":"https:\/\/utopia.p82.it\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/utopia.p82.it\/#\/schema\/logo\/image\/","url":"https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/02\/logo-utopia-v-buona.jpg","contentUrl":"https:\/\/www.utopiasis.it\/wp-content\/uploads\/2024\/02\/logo-utopia-v-buona.jpg","width":569,"height":191,"caption":"utopia sis"},"image":{"@id":"https:\/\/utopia.p82.it\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.utopiasis.it\/en\/wp-json\/wp\/v2\/pages\/1038","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.utopiasis.it\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.utopiasis.it\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.utopiasis.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.utopiasis.it\/en\/wp-json\/wp\/v2\/comments?post=1038"}],"version-history":[{"count":3,"href":"https:\/\/www.utopiasis.it\/en\/wp-json\/wp\/v2\/pages\/1038\/revisions"}],"predecessor-version":[{"id":1041,"href":"https:\/\/www.utopiasis.it\/en\/wp-json\/wp\/v2\/pages\/1038\/revisions\/1041"}],"wp:attachment":[{"href":"https:\/\/www.utopiasis.it\/en\/wp-json\/wp\/v2\/media?parent=1038"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}